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Plasmid pMJ05-Ara-lacS-2912-RBM-3´UTR and plasmid pMJ05-Ara-lacS-

1742-RBM-3´UTR:
The 2912-RBM and 1742-RBM sequences, respectively, were inserted into plasmid pMJ05-Ara-lacS-lacS-3´UTR using overlap PCR. First, the sub-sequence 5´-TCAAGTCTCACTATACCAAA-3´ in the lacS-3´ UTR present in pSAV5 (29) was replaced by the 2912-RBM (5´-GGAAGTATTGGGAGGAATGAA-3´; lacS 2912-RBM-3'UTR) and the 1742-RBM (5´-GGATGGATATTAGGTACTGGG -3´; lacS 1742-RBM-3'UTR), respectively. The overlap PCR for 2912-RBM insertion was performed using the oligonucleotides 5'-ccggCCTAGGGCACCATATGTTTAG-3' containing an AvrII site (underlined) together with 5´-
GGAAGTATTGGGAGGAATGAAGTATGAGTTTTCTTTTAATCTTATTC-3´ and oligonucleotides 5´-TTCATTCCTCCCAATACTTCCGAAAGTGGGGCCCCTTAG -3´
together with 5´-GAAGCGAGAAGAATCATAATGG-3´ and pSAV5 as template. The overlap PCR for 1742-RBM insertion was performed using the oligonucleotides 5'-ccggCCTAGGGCACCATATGTTTAG-3' containing an AvrII site (underlined) together with 5´-GGATGGATATTAGGTACTGGGGTATGAGTTTTCTTTTAATCTTATTC -3´
and oligonucleotides 5´-CCCAGTACCTAATATCCATCCGAAAGTGGGGCCCCTTAG -3´ together with 5´-GAAGCGAGAAGAATCATAATGG-3´ and pSAV5 as template.
The second PCR was performed using the annealed PCR products as template together with oligonucleotides 5´-ccggCCTAGGGCACCATATGTTTAG-3´ containing an AvrII restriction site (underlined) and 5´-GAAGCGAGAAGAATCATAATGG-3´, which binds 3´ of the EagI site present in the template. The PCR products Ara-lacS-2912-RBM-3´UTR and Ara-lacS-1742-RBM-3´UTR was cleaved with AvrII and EagI and ligated into the corresponding sites of plasmid pMJ05 (29), giving rise to plasmids pMJ05-Ara-lacS-2912-RBM-lacS-3´UTR
and pMJ05-Ara-lacS-1742-RBM-lacS-3´UTR, respectively.
Plasmid pMJ05-tf55α-lacS-2194-RBM-3'UTR: As described above, the Ara-
lacS-2194-RBM-3´UTR generated by overlap-PCR was cleaved with NcoI and EagI
to remove the Ara promoter. The fragment lacS-2194-RBM-3´UTR was then ligated into the corresponding sites of plasmid pSAV11 (29), resulting in plasmid pSAV11-tf55α-lacS-2194-RBM-3'UTR. The tf55α-lacS-2194-RBM-3'UTR was finally cloned into the AvrII and EagI sites of plasmid pMJ05 (29), resulting in plasmid pMJ05-tf55α-lacS-2194-RBM-lacS-3´UTR.
Plasmids pMJ05-Ara-lacS-2194-3´UTR and pMJ05-tf55α-lacS-2194-3´UTR:
To generate the lacS-2194-3´UTR reporter constructs, 250 nt of the 2194-3´UTR
(coordinates: 2017993-2018243) were PCR amplified using the oligonucleotides 5´-ccggGGGCCCTTATATATTTGGAGGTAGTAAG-3´ containing an ApaI restriction site (underlined) and 5´-ggccCGGCCGGAGGTGGAACCTCAACAG-3´ containing an
EagI restriction site (underlined). The PCR product was cleaved with ApaI and EagI, and then inserted into the corresponding restriction sites of plasmid pSAV5, containing the Ara-promoter, and of pSAV11, containing the tf55α-promoter, respectively, resulting in plasmids pSAV5/pSAV11-lacS-2194-3'UTR. The respective
AvrII-EagI fragments were reisolated from the latter plasmids and inserted into plasmid pMJ05 cleaved with the same enzymes (loss of the tf55α-promoter), resulting in plasmids pMJ05-Ara-lacS-2194-3´UTR and pMJ05-tf55α-lacS-2194-3´UTR, respectively.
Plasmid pMJ05-tf55α-lacS-∆2194-RBM-2194-3'UTR:
The replacement of the 2194-RBM in plasmid pMJ05-tf55α-lacS-2194-3´UTR was generated by overlap PCR. The overlap PCR was performed using the template pSAV5 lacS-2194-3'UTR, containing the Ara-promoter, together with the oligonucleotide pair 5´-ccggCCTAGGGCACCATATGTTTAG-3´ (AvrII restriction site is underlined) and 5´-GCGATGGTATGGTGGGCCAGAATATGCTTATAGCCAAATCTTAC-3´ as well as the oligonucleotide pair 5´-TTCTGGCCCACCATACCATCGC-TTTCTTATCATTATAATAATCAT-3´ and 5´-GAAGCGAGAAGAATCATAATGG-3´, which binds 3´ of the EagI site present in the template. The second PCR was performed using the annealed PCR products as template together with the oligonucleotides 5'-ccggCCTAGGGCACCATATGTTTAG-3' (AvrII restriction site is underlined) and 5´-GAAGCGAGAAGAATCATAATGG-3´, which binds 3´ of the EagI site present in the template. The PCR product was cleaved with AvrII and EagI and ligated into the corresponding sites of plasmid pMJ05, resulting in plasmid pMJ05-Ara-lacS-∆2194-RBM-2194-3'UTR. In addition, the PCR product was cleaved with
ApaI and EagI and cloned into the corresponding sites of plasmid pSAV11, resulting in plasmid pSAV11-lacS-∆2194-RBM-2194-3´UTR. The latter plasmid was cleaved with AvrII and EagI and the corresponding fragment was inserted into the AvrII and EagI sites of plasmid pMJ05, resulting in plasmid pMJ05-tf55α-lacS-∆2194-RBM-
2194-3´UTR.
The pSAV5-and pSAV11 constructs were transformed into E. coli Top10 (Thermo Fisher scientific). The transformed cells were grown on LB-plates supplemented with 100 µg/ml ampicillin at 37°C. The ligated pMJ05 derivatives were transformed in E. coli Top10 and the transformed cells were grown on LB-plates containing 50 µg/ml ampicillin at 20°C. All constructed plasmids were verified by restriction digests and the corresponding inserts were validated by DNA sequencing.
All Sso shuttle plasmids were transformed by electroporation in Sso PH1-16 (∆pyrEF; ∆lacS), and the selection of plasmid bearing cells was performed as described (29).
Genomic DNA was isolated from the corresponding strains and the correct insertion of the respective DNA fragments was confirmed by PCR using the oligonucleotides 5´-GGATGCTAAACAACTATTCAAACTG-3´ and 5´-GTTGTGTGGAATTGTGAGCGGATAA-3´ followed by DNA sequencing of the PCRproducts.
Analytical size-exclusion chromatography
Analytical size-exclusion chromatography (ASEC) was performed with a Superdex S200 10/300 GL column (GE Healthcare) equilibrated in buffer containing 20 mM HEPES (pH 7.5),150 mM NaCl, 1 mM β-mercaptoethanol and 5 mM MgCl 2 . ASEC was carried out at 20°C with a flow rate of 0.5 ml/min using a HPLC device (Agilent Technologies 1260 infinity). 50 µl of the SmAP2-RBM (72 pmol/µl) and the (SmAP2) 7 -protein (36 pmol/µl) were either injected alone or 25 µl of SmAP2-RBM (144 pmol/µl) and the (SmAP2) 7 protein (72 pmol/µl) were mixed in a 2:1 molar ratio and incubated at 65°C for 10 min before injection. On-line detection was performed with a miniDawn Treos detector (Wyatt Technology Corp., Santa Barbara, CA). Table S1 . Localization of the SmAP2-RBM present in 53 mRNAs enriched with SmAP2 (15). The coding sequence (ORF) and the first 100 nucleotides of the 3´UTR were used as input sequences for motif identification using the MEME tool A) The genome coordinates and the genomic context of the Sso 1742 gene, encoding a subunit of the terminal quinol oxidase (DoxD), are indicated. The 1742-RBM sequence 5´-GGAUGGAUAUUAGGUACUGGG-3´ at position 1580272-1580251 was identified using the MEME online tool (Table S1 ). The alignment with the SmAP2-cRBM is depicted below.
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B)
The genome coordinates and the genomic context of the Sso 2194 gene, encoding a putative thermopsine, are indicated. The 2194-RBM sequence 5´-GGAGAUAUAGUAGGAUAG-3´ at position 2018033-2018054 was identified using the MEME online tool (Table S1 ). The alignment with the SmAP2-cRBM is depicted below.
C) The genome coordinates and the genomic context of the Sso 2912 gene, encoding a sulfate adenylyltransferase (sat), are indicated. The 2912-RBM sequence 5´ GGAAGUAUUGGGAGGAAUGAA-3´ at position 2663944-2663965 was identified using the MEME online tool (Table S1 ). The alignment with the SmAP2-cRBM is depicted below. A) LacS mRNA levels and β-Galactosidase activity in sucrose and arabinose. The Sso strain PH1-16(pMJ05-Ara/ lacS-3'UTR) was grown to an OD 600 of 0.4 in Brock´s medium containing 20 % sucrose or 20 % arabinose. Total RNA isolation and reverse transcription was performed as described in Materials and Methods. The lacS mRNA levels were determined using qPCR as described in Materials and Methods. The β-
Galactosidase activity was determined as described in Materials and Methods.
Decrease of lacS mRNA levels after promoter shut-off upon shift to sucrosecontaining medium. The Sso strains PH1-16(pMJ05-Ara-lacS-3'UTR) and PH1-16(pMJ05-Ara-lacS-2194-RBM-3'UTR) were grown in Brock's medium at 75°C containing 0.2% arabinose to an OD 600 of 0.5. The cells were pelleted and resuspended in the same volume of Brock's medium containing 0.2% sucrose prewarmed to 75°C (= 0 min). After 2h and 4h, 10 ml of the cultures were withdrawn, total RNA was isolated and cDNA was generated as described in Materials and
Methods. The lacS mRNA levels at the different time points after promoter shut-off were determined using total RNA from Sso expressing either lacS with the authentic
lacS-3´UTR (lacS-3´UTR / grey bar) or lacS bearing the 2194-RBM in the lacS-3'UTR
(lacS 2194-RBM-3'UTR / red bar). The lacS levels were normalized to 16S rRNA.
The lacS levels at time 0 were set to 100%. 
